Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype
暂无分享,去创建一个
N. Schultz | M. Berger | C. Iacobuzio-Donahue | S. Leach | D. Solit | O. Basturk | W. Jarnagin | G. Abou-Alfa | A. Zehir | E. Jordan | L. Saltz | J. Hechtman | R. Ptashkin | J. Harding | M. Lowery | A. Varghese | D. Klimstra | D. Hyman | P. Allen | V. Balachandran | M. Schattner | G. Askan | Kenneth H. Yu | E. O’Reilly | B. Herbst | D. Glassman | Christina M. Covington | Hannah Maynard | T. Leach
[1] R. Hruban,et al. Surgical and molecular pathology of pancreatic neoplasms , 2016, Diagnostic Pathology.
[2] R. Gibbs,et al. Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.
[3] J. Potash,et al. Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. , 2016, Cancer discovery.
[4] Roman Rouzier,et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials , 2015, Journal of the National Cancer Institute.
[5] G. Petersen,et al. Familial Pancreatic Adenocarcinoma. , 2015, Hematology/oncology clinics of North America.
[6] David M. Thomas,et al. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial , 2015, Clinical Cancer Research.
[7] G. Petersen,et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. , 2015, Gastroenterology.
[8] J. Kench,et al. Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.
[9] Ayala Hubert,et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Gershoni-baruch,et al. Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers , 2014, British Journal of Cancer.
[11] Benjamin D. Smith,et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.
[12] Laura H. Tang,et al. Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC). , 2014 .
[13] G. Batist,et al. Use of statins and the risk of death in patients with prostate cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Jill P. Mesirov,et al. Criteria for the use of omics-based predictors in clinical trials , 2013, Nature.
[15] R. Schmutzler,et al. Olaparib monotherapy in patients with advanced cancer and a germ-line BRCA1/2 mutation: An open-label phase II study. , 2013 .
[16] Yuchen Jiao,et al. ATM mutations in patients with hereditary pancreatic cancer. , 2012, Cancer discovery.
[17] M. Robson,et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. , 2011, The oncologist.
[18] M. Nowak,et al. Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.
[19] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[20] R H Hruban,et al. Progression model for pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] R. Hruban,et al. Progress in cancer genetics: lessons from pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.